When drugs are expected to get FDA approval and show positive data but don't, the underlying stocks of drug and biotech companies can see harsh punishment.
The top analyst upgrades, downgrades and initiations seen from Monday include Canadian Solar, Constellation Brands, Eli Lilly, Incyte, McDonald's and Snap.
With earnings starting to really snowball next week, and a market that seems to be teetering somewhat due to high valuations and some messy geopolitical issues, it makes sense for investors to…
A massive new Jefferies research report reminds investors that as a rule the first quarter is traditionally slower for biotechnology stocks.
The first quarter's top-performing stocks in the S&P 500 index included two pharmaceutical firms, an electricity generator, a video game maker and a media company.
24/7 Wall St. tracked the best performing members of the S&P 500 Index on a year-to-date basis. It turns out that seven of the 500 stocks have gains of between 30% and…
Gilead Sciences has long been in need of a catalyst to move its business, and a lot of investors and analysts alike have considered this company dead money until something happens.
24/7 Wall St. has put together a preview of Express Scripts, T-Mobile and some of the other most anticipated quarterly earnings reports that are on deck for Tuesday.
Shares of Calithera Biosciences saw a solid gain early on Monday after the company reported a global collaboration and licensing agreement with Incyte.
Chris Lange Credit Suisse sees future earnings growth from Incyte’s pipeline, with epacadostat’s potential as a best-in-class immunotherapy combination agent making the stock an attractive takeout target.
Chris Lange Stocks have pulled back off their highs from the end of 2016 and that Dow Jones Industrial Average (DJIA) 20,000 mark remains elusive. The major market indexes were indicated a tad lower…
Needless to say, the past two years have been rough on biotech. The question for investors is which of the stocks hold the best potential in 2017.
A new Jefferies research report makes the case that five top biotech companies may be right in the cross-hairs of the biotech giants or perhaps large pharmaceutical companies.
In a new research report, Baird notes two biotech companies in its research coverage universe that may be considered speculative takeover targets, and a third is a possible target as well.
The Jefferies Healthcare Conference wrapped up in New York City last week, and the mood was reported as generally positive, with investors feeling much better than a few months ago.
